Derek John Hausenloy

Professor

Email

Contact: 66015121

Dr. Hausenloy is Professor at Duke-NUS Medical School and is a Senior Consultant Cardiologist and Clinician Scientist at the National Heart Centre, Singapore. He is also Professor at University College London, UK, and is Adjunct Professor at Yong Loo Lin School of Medicine, NUS. He conducts both basic and clinical research in the area of ischaemic heart disease, heart failure, cardioprotection and cardiac MRI. His research focus is on discovering novel therapies for protecting the heart against the detrimental effects of acute ischaemia  / reperfusion injury in order to prevent the onset of heart failure.

He uses a translational approach to cardioprotection ranging from cellular and animal models of acute IRI to proof-of-concept clinical studies in acute myocardial infarction and cardiac bypass surgery patients, and finally to large multi-center randomised clinical trials focused on clinical outcomes.

Other areas of research focus include nanoparticle design to deliver protective therapies to the ischaemic heart and atherosclerotic plaques, and use of inducible pluripotential stem cells (IPSC)-derived cardiomyocytes for cardiac disease modelling of cardiomyopathies. 

He has been PI on over 30 research grants, and has authored over 270 papers and his H-index is 87 (total citations 30,699). In 2018, he was named Highly Cited Researcher (top 1% by citations for field and year in Web of Science), and in 2020 he was awarded the Dean's Excellence Award in Research 2019, Duke-NUS.

Cardioprotection: Bench to Bedside
Ischaemic heart disease (IHD) is the leading cause of death and disability in Singapore and worldwide. As such novel treatment strategies are required to protect the heart against the detrimental effects of acute ischaemia/reperfusion injury (IRI) - this is essential and is required to preserve cardiac function and prevent the onset of heart failure in patients with IHD. This is particularly important in IHD patients undergoing coronary artery bypass graft (CABG) surgery and in IHD patients presenting with an acute myocardial infarction (AMI) in which mortality and morbidity remain significant. Therefore, our main research objective is to discover novel therapeutic strategies for protecting the myocardium from acute IRI (a strategy termed ‘cardioprotection’).

We use a translational approach to cardioprotection with the identification of novel therapeutic targets at the laboratory ‘bench’ using pre-clinical models of acute IRI, and investigate their therapeutic potential in proof-of-concept clinical studies and multi-centre clinical outcome randomised controlled trials in IHD patients undergoing CABG surgery and in IHD patients presenting with an AMI.  

Main research interests
• Mitochondria as targets for cardioprotection
• Ischaemic preconditioning and postconditioning – underlying signalling pathways, mechanisms and clinical application 
• Remote ischaemic conditioning – underlying mechanisms and clinical application 
• Effect of co-morbidities such as diabetes on cardioprotection
• Pre-clinical and clinical cardiac MRI and hybrid PET/MR studies to investigate the pathophysiology of acute IRI and assess cardioprotection in the setting of AMI and post-ischaemic heart failure.
• Clinical cardioprotection proof-of-concept and multi-centre outcome studies in CABG and AMI patients

PUBLICATIONS (selected publications)
274 publications, H-index 87 Citation 30,699

1. Gorog DA, Farag M, Spinthakis N, Yellon DM, Bøtker HE, Kharbanda RK, Hausenloy DJ. Effect of remote ischaemic conditioning on platelet reactivity and endogenous fibrinolysis in ST-elevation myocardial infarction- a substudy of the CONDI-2/ERIC-PPCI randomised controlled trial.

Cardiovasc Res. 2020 Mar 12. pii: cvaa061. doi: 10.1093/cvr/cvaa061. [Epub ahead of print]. IF 7.014.

2. Nagel, E, Greenwood J, McCann GP, Shah AJ, Hussain ST, Plein S, Bucciarelli-Ducci C, Paul M, Westwood MA, Marber M, Richter WS, Puntmann VO, Shwenke C, Schulz-Menger J, Das R,  Hausenloy DJ, Steen H, Berry C.
Comparative Effectiveness of Magnetic Resonance Perfusion and Fractional Flow Reserve
N Engl J Med 2019 June 6. IF 70.67. 

3. Hausenloy DJ, Kharbanda RK, Møller UK, Ramlall M, Aarøe J, Butler R, Bulluck H, Clayton T, Dana A, Dodd M, Engstrom T, Evans R, Lassen JF, Christensen EF, Garcia-Ruiz JM, Gorog DA, Hjort J, Houghton RF, Ibanez B, Knight R, Lippert FK, Lønborg JT, Maeng M, Milasinovic D, More R, Nicholas JM, Jensen LO, Perkins A, Radovanovic N, Rakhit RD, Ravkilde J, Ryding AD, Schmidt MR, Riddervold IS, Sørensen HT, Stankovic G, Varma M, Webb I, Terkelsen CJ, Greenwood JP, Yellon DM, Bøtker HE; CONDI-2/ERIC-PPCI Investigators. Effect of remote ischaemic conditioning on clinical outcomes in patients with acute myocardial infarction (CONDI-2/ERIC-PPCI): a single-blind randomised controlled trial.
Lancet. 2019 Oct 19;394(10207):1415-1424. doi: 10.1016/S0140-6736(19)32039-2. IF 59.102.

4. Ibanez B, Aletras AH, Arai AE, Arheden H, Bax J, Berry C, Bucciarelli-Ducci C, Croisille P, Dall'Armellina E, Dharmakumar R, Eitel I, Fernández-Jiménez R, Friedrich MG, García-Dorado D, Hausenloy DJ, Kim RJ, Kozerke S, Kramer CM, Salerno M, Sánchez-González J, Sanz J, Fuster V. Cardiac MRI Endpoints in Myocardial Infarction Experimental and Clinical Trials: JACC Scientific Expert Panel.
J Am Coll Cardiol. 2019 Jul 16;74(2):238-256. doi: 10.1016/j.jacc.2019.05.024. IF 18.639.

5. Hausenloy DJ, Heusch G. Translating Cardioprotection for Patient Benefit: The EU-CARDIOPROTECTION COST Action.
J Am Coll Cardiol. 2019 Apr 23;73(15):2001-2003. doi: 10.1016/j.jacc.2019.03.020. IF 18.639.

6. Davidson SM, Ferdinandy P, Andreadou I, Bøtker HE, Heusch G, Ibáñez B, Ovize M, Schulz R, Yellon DM, Hausenloy DJ*, Garcia-Dorado D*; CARDIOPROTECTION COST Action (CA16225). Multitarget Strategies to Reduce Myocardial Ischemia/Reperfusion Injury: JACC Review Topic of the Week. *Joint Senior Authors.
J Am Coll Cardiol. 2019 Jan 8;73(1):89-99. doi: 10.1016/j.jacc.2018.09.086. IF 18.639.

7. Bulluck H, Hausenloy DJ
Modulating NAD+ metabolism to prevent acute kidney injury.
Nat Med. 2018 Sep;24(9):1306-1307. IF 30.641

8. Bulluck H, Chan MHH, Paradies V, Bryant JA, Hernández-Reséndiz S, Cabrera-Fuentes HA, Watson TJ, Chan MY, Tan JW, Hausenloy DJ. Impact of Cardioprotective Therapies on the Edema-Based Area at Risk by CMR in Reperfused STEMI.
J Am Coll Cardiol. 2018 Jun 19;71(24):2856-2858. IF 18.639.

9. Bulluck H, Dharmakumar R, Arai AE, Berry C, Hausenloy DJ. Cardiovascular Magnetic Resonance in Acute ST-Segment-Elevation Myocardial Infarction: Recent Advances, Controversies, and Future Directions.
Circulation. 2018 May 1;137(18):1949-1964. doi: 10.1161/CIRCULATIONAHA.117.030693. IF 23.054.

10. Hausenloy DJ, Yellon DM. Combination Therapy to Target Reperfusion Injury After ST-Segment-Elevation Myocardial Infarction: A More Effective Approach to Cardioprotection.
Circulation. 2017 Sep 5;136(10):904-906. doi: 10.1161/CIRCULATIONAHA.117.029859. IF 23.054.

11. Thielmann M, Sharma V, Al-Attar N, Bulluck H, Bisleri G, Jh Bunge J, Czerny M, Ferdinandy P, Frey UH, Heusch G, Holfeld J, Kleinbongard P, Kunst G, Lang I, Lentini S, Madonna R, Meybohm P, Muneretto C, Obadia JF, Perrino C, Prunier F, Sluijter JPG, Van Laake LW, Sousa-Uva M, Hausenloy DJ. ESC Joint Working Groups on Cardiovascular Surgery and the Cellular Biology of the Heart Position Paper: Perioperative myocardial injury and infarction in patients undergoing coronary artery bypass graft surgery.
Eur Heart J. 2017 Aug 14;38(31):2392-2407. IF 24.889.

12. Madonna R, Van Laake LW, Davidson SM, Engel FB, Hausenloy DJ, Lecour S, Leor J, Perrino C, Schulz R, Ytrehus K, Landmesser U, Mummery CL, Janssens S, Willerson J, Eschenhagen T, Ferdinandy P, Sluijter JP. Position Paper of the European Society of Cardiology Working Group Cellular Biology of the Heart: cell-based therapies for myocardial repair and regeneration in ischemic heart disease and heart failure.
Eur Heart J. 2016 Jun 14;37(23):1789-98. doi: 10.1093/eurheartj/ehw113. IF 24.889.

13. Hausenloy DJ, Yellon DM. Ischaemic conditioning and reperfusion injury.
Nat Rev Cardiol. 2016 Apr;13(4):193-209. IF 14.299.

14. Hausenloy DJ, Botker HE, Engstrom T, Erlinge D, Heusch G, Ibanez B, Kloner RA, Ovize M, Yellon DM, Garcia-Dorado D. Targeting reperfusion injury in patients with ST-segment elevation myocardial infarction: trials and tribulations.
Eur Heart J. 2016 Apr 1;38(13):935-941. IF 24.889.

15. Hausenloy DJ, Candilio L, Evans R, Ariti C, Jenkins DP, Kolvekar S, Knight R, Kunst G, Laing C, Nicholas J, Pepper J, Robertson N, Xenou X, Clayton T, Yellon DM. Remote Ischemic Preconditioning and Outcomes in Cardiac Bypass Surgery.
N Engl J Med 2015 Oct 8;373(15):1408-17. IF 70.67. 

16. Hausenloy DJ, Yellon DM. Targeting Myocardial Reperfusion Injury--The Search Continues.
N Engl J Med. 2015 Sep 10;373(11):1073-5. IF 70.67. 

17. Hausenloy DJ, Kharbanda R, Schmidt MR, Møller UK, Ravkilde J, Jensen LO, Engstrøm T, García Ruiz JM, Radovanovic N, Christensen EF, Sørensen HT, Ramlall M, Bulluck H, Evans R, Nicholas J, Knight R, ClaytonT, Yellon DM, Bøtker HE. Effect of remote ischemic conditioning on clinical outcomes in patients presenting with a ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
Eur Heart J. 2015 Aug 1;36(29):1846-8. IF 24.889.

18. Yellon DM, Ackbarkhan A, Balgobin V, Bulluck H, Deelchand A, Dhuny M, Domah N, Gaoneadry D, Jagessur RK, Joonas N, Kowlessur S, Lutchoo J, Nicholas J, Pauvaday K, Shamloll O, Walker JM, Hausenloy DJ. Remote ischemic conditioning reduces myocardial infarct size in STEMI patients treated by thrombolysis: The ERIC-LYSIS study.
J Am Coll Cardiol 2015 Jun 30;65(25):2764-5. IF 18.639.

19. Fröhlich GM, Meier P, White SK, Yellon DM, Hausenloy DJ. Myocardial reperfusion injury: looking beyond primary PCI.
Eur Heart J. 2013 Jun;34(23):1714-22. IF 24.889.

20. Hausenloy DJ, Yellon DM. Myocardial ischemia-reperfusion injury: a neglected therapeutic target.
J Clin Invest. 2013 Jan 2;123(1):92-100. IF 13.765

21. Babu GG, Walker JM, Yellon DM, Hausenloy DJ. Peri-procedural myocardial injury during percutaneous coronary intervention: an important target for cardioprotection.
Eur Heart J. 2011 Jan;32(1):23-31. IF 24.889.

22. Hausenloy DJ, Opie, L, Yellon DM. Dissociating HDL cholesterol from cardiovascular risk.
Lancet. 2010 Jul 31;376(9738):305-6. IF 59.102.

23. Hausenloy DJ, Yellon DM. Cell membrane repair as a novel mechanism in ischemic preconditioning?
Circulation 2010 Jun 15;121(23):2547-9. IF 23.054.

24. Ong SB, Arjun S, Lim SY, Yellon DM, Davidson SM, Hausenloy DJ. Inhibiting mitochondrial fission protects the heart against ischemia reperfusion injury
Circulation 2010 May 11;121(18):2012-22. IF 23.054.
(** Article selected by Julie Bossuyt and Donald Bers for the Faculty of 1000 Biology)
(** Circulation Editors' Picks: Most Read Articles on Studies Performed in an Animal Model)
(** Circulation Editors' Picks: Most Read Articles in Molecular Cardiology)

25. Yellon DM, Hausenloy DJ. Myocardial Reperfusion Injury.
N Engl J Med 2007 Sep 13;357(11):1121-35. IF 70.67. 

26. Hausenloy DJ, Mwamure P, Venugopal V, Harris J, Barnard M, Grundy E, Ashley E, Kolvekar S, Hayward M, Keogh B, MacAllister R, Yellon DM. The effect of remote ischemic preconditioning during coronary artery bypass graft surgery: a randomised controlled trial.
Lancet 2007 Aug 18;370(9587):575-9. IF 59.102.